TransMedics Group (NASDAQ:TMDX) Coverage Initiated by Analysts at Piper Sandler

Piper Sandler assumed coverage on shares of TransMedics Group (NASDAQ:TMDXFree Report) in a report released on Thursday, Marketbeat reports. The brokerage issued an overweight rating and a $95.00 target price on the stock.

TMDX has been the subject of several other research reports. JPMorgan Chase & Co. upped their target price on TransMedics Group from $87.00 to $105.00 and gave the stock an overweight rating in a research report on Tuesday, February 27th. Morgan Stanley upped their target price on TransMedics Group from $75.00 to $95.00 and gave the stock an equal weight rating in a research report on Wednesday, February 28th. Finally, Oppenheimer upped their target price on TransMedics Group from $92.00 to $105.00 and gave the stock an outperform rating in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, TransMedics Group currently has an average rating of Moderate Buy and a consensus price target of $102.00.

Check Out Our Latest Stock Report on TMDX

TransMedics Group Stock Performance

Shares of TMDX stock opened at $73.94 on Thursday. The stock has a fifty day moving average price of $83.45 and a 200 day moving average price of $70.01. The stock has a market cap of $2.42 billion, a PE ratio of -96.03 and a beta of 2.01. TransMedics Group has a 1 year low of $36.42 and a 1 year high of $99.63. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30.

TransMedics Group (NASDAQ:TMDXGet Free Report) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The firm had revenue of $81.20 million during the quarter, compared to the consensus estimate of $68.49 million. During the same quarter in the previous year, the business earned ($0.21) earnings per share. The firm’s quarterly revenue was up 158.6% compared to the same quarter last year. Sell-side analysts forecast that TransMedics Group will post -0.22 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Tamer I. Khayal sold 2,330 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $90.09, for a total transaction of $209,909.70. Following the completion of the transaction, the insider now directly owns 14,375 shares of the company’s stock, valued at $1,295,043.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Tamer I. Khayal sold 2,330 shares of the stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $90.09, for a total value of $209,909.70. Following the completion of the transaction, the insider now directly owns 14,375 shares of the company’s stock, valued at approximately $1,295,043.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Stephen Gordon sold 15,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $77.07, for a total value of $1,156,050.00. Following the completion of the transaction, the chief financial officer now directly owns 13,075 shares of the company’s stock, valued at $1,007,690.25. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 92,949 shares of company stock valued at $7,710,719. 6.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC grew its holdings in TransMedics Group by 42.5% in the 3rd quarter. FMR LLC now owns 4,714,870 shares of the company’s stock worth $258,139,000 after buying an additional 1,407,171 shares in the last quarter. BlackRock Inc. boosted its stake in TransMedics Group by 2.4% during the 2nd quarter. BlackRock Inc. now owns 2,309,393 shares of the company’s stock valued at $193,943,000 after purchasing an additional 54,776 shares in the last quarter. Vanguard Group Inc. boosted its stake in TransMedics Group by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock valued at $147,214,000 after purchasing an additional 50,673 shares in the last quarter. Driehaus Capital Management LLC boosted its stake in TransMedics Group by 8.4% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,162,214 shares of the company’s stock valued at $97,603,000 after purchasing an additional 90,023 shares in the last quarter. Finally, Eventide Asset Management LLC boosted its stake in TransMedics Group by 7.4% during the 4th quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock valued at $78,475,000 after purchasing an additional 68,884 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

(Get Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Further Reading

Analyst Recommendations for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.